Mahindra Manulife Multi Cap Fund
The scheme seeks to provide medium to long term capital appreciation through appropriate diversification and taking low risk on business quality.
Growthvine rating: 5/5 — ranked #2 of 34 in category.
Fund basics
| Category | Equity: Multi Cap |
|---|
| NAV | ₹37.74 (as of 2026-10-01) |
|---|
| AUM | ₹7,184 Cr |
|---|
| Expense ratio | 1.53% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Neelesh Dhamnaskar |
|---|
| Exit load | 1% for redemption within 3 months |
|---|
Performance & risk
| 5-year annualised return | 13.17% |
|---|
| Sharpe ratio | 0.71 |
|---|
| Standard deviation | 16.47% |
|---|
| Max drawdown | −34.53% |
|---|
| Alpha | 3.99 |
|---|
| Beta | 0.95 |
|---|
Over 5 years, captured 104.3% of NIFTY500 Multicap 50:25:25's upside and 96.6% of its downside.
Market cap allocation
| Large cap | 40.7% |
|---|
| Mid cap | 32.4% |
|---|
| Small cap | 27.0% |
|---|
Concentration
| Top 5 holdings | 19.5% |
|---|
| Top 10 holdings | 31.1% |
|---|
| Total holdings | 71 |
|---|
| Index overlap | 22.6% |
|---|
| Active share | 77.4% |
|---|
Top holdings
- Triparty Repo — 8.7%
- Multi Commodity Exchange of India Ltd — 4.9%
- Neuland Laboratories Limited. — 4.0%
- Divis Laboratories Ltd. — 3.9%
- ICICI Bank Ltd. — 3.5%
- Adani Enterprises Ltd. — 3.2%
- Oil India Limited — 2.6%
- APL Apollo Tubes Limited — 2.5%
- Torrent Pharmaceuticals Ltd. — 2.4%
- PTC Industries Ltd. — 2.1%
Top sectors
- Banking & Financial — 16.0%
- Pharma & Biotech — 14.8%
- Cash — 10.0%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 4.8% | Q1 (Top) | #8 of 34 |
| 2025 | 3.4% | Q2 | #14 of 31 |
| 2024 | 23.4% | Q2 | #12 of 24 |
| 2023 | 34.2% | Q2 | #7 of 17 |
| 2022 | 1.6% | Q3 | #8 of 13 |